More Education

Blog Commonsense State Rules Ease Access to Biosimilars

Health care in the United States has quietly turned a big corner. Just as the FDA approved its first interchangeable biosimilar, Oklahoma became the 50th and final state where pharmacists can substitute these lower-cost versions of biologic drugs.

Read More

Related Content

Paper Focus on Access: Navigating Medicare Part B Negotiation and Its Unintended Consequences Brief

Paper What Patients Should Know About Biologics

Event Report AfPA’s 2024 National Policy & Advocacy Summit Report

Stay Informed View the latest newsletter

To receive regular newsletters and periodic alerts from the BPC, enter your email address in the form below:

(function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[2]='LNAME';ftypes[2]='text';}(jQuery));var $mcj = jQuery.noConflict(true);